Rezolute: Wedbush upgrade to Outperform with $5 price targe

 

Rezolute (RZLT) shares rose sharply on March 25, 2026, following an analyst upgrade from Wedbush that raised the price target from $2 to $5. This positive revision came shortly after the company's March 24 announcement detailing a constructive Type B FDA meeting held on March 17. In that meeting, despite the Phase 3 sunRIZE trial for ersodetug in congenital hyperinsulinism missing its primary endpoint, the FDA encouraged submission of full study reports, datasets, and open-label extension data for independent review rather than dismissing the program. The agency is expected to provide further feedback in the second half of 2026. The upgrade reflects the analyst's view that a worst-case regulatory outcome now appears unlikely, leading to the re-addition of the congenital HI program to their valuation model (with modest probability of success). The stock had already gained over 12% on March 24 with elevated volume on the FDA news, with additional momentum building into the next trading session amid the analyst action.

https://finviz.com/quote.ashx?t=RZLT